Sarcoma: open trials in Canada

• NCT07227961

  Activation Sarcoma: PROMIS and Mobility Evaluation in Sarcoma Patients

  Research · University of Calgary

  Foothills Medical Centre, Arthur J Child Comprehensive Cancer Centre, University of Calgary, Calgary · Mount Sinai Hospital, University of Toronto, Toronto

  Registry updated 2026-11-02

• NCT06395103

  Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC

  Alberta Children's Hospital ( Site 1227), Calgary · McGill University Health Centre-Pediatric HematologyOncology ( Site 1223), Montreal · The Hospital for Sick Children ( Site 1225), Toronto

  Registry updated 2026-10-30

• NCT06345729

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  QEII Health Sciences Centre - Victoria General Site-Dept. of Medical Oncology ( Site 0208), Halifax · Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0205), Hamilton · St. Marys Hospital Center ( Site 0204), Montreal · Sunnybrook Research Institute ( Site 0206), Toronto · Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0207), Trois-Rivières · CancerCare Manitoba ( Site 0210), Winnipeg

  Registry updated 2026-10-26

• NCT06422806

  Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

  Trial Treatment · Phase 3 · National Cancer Institute (NCI)

  Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Cross Cancer Institute, Edmonton · Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton · Ottawa Hospital and Cancer Center-General Campus, Ottawa · CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Québec · University Health Network, Princess Margaret Hospital, Toronto · BCCA - Vancouver Cancer Centre, Vancouver · CancerCare Manitoba, Winnipeg

  Registry updated 2026-10-26

• NCT07297667

  GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

  Trial Treatment · Phase 1 · Canadian Cancer Trials Group

  Arthur J.E. Child Comprehensive Cancer Centre, Calgary · The Research Institute of the McGill University, Montreal · Ottawa Hospital Research Institute, Ottawa · University Health Network, Toronto

  Registry updated 2026-10-16

• NCT07820033

  Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial

  Trial Treatment · Phase 2 · University Health Network, Toronto

  University Health Network, Toronto

  Registry updated 2026-10-15

• NCT06805773

  Evaluating the Use of Educational Videos in Newly Diagnosed Patients in a Medical Oncology Sarcoma Clinic

  Trial Treatment · Mount Sinai Hospital, Canada

  Mount Sinai Hospital, Toronto

  Registry updated 2026-10-14

• NCT07541170

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  Trial Treatment · Phase 3 · Hoffmann-La Roche

  Jewish General Hospital, Montreal

  Registry updated 2026-10-13

• NCT07261631

  Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

  Trial Treatment · Phase 1 · Novartis Pharmaceuticals

  Novartis Investigative Site, Montreal

  Registry updated 2026-10-09

• NCT04031677

  Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

  Trial Treatment · Phase 3 · European Organisation for Research and Treatment of Cancer - EORTC

  London Regional Cancer Center, London · Hôpital Maisonneuve-Rosemont, Montreal · The Research Institute of the McGill University Health Centre, Montreal · The Ottawa Hospital - General Campus, Ottawa · Mount Sinai Hospital, Toronto · BCCA - Vancouver Cancer Centre, Vancouver

  Registry updated 2026-10-07

• NCT06541262

  Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  Trial Treatment · Phase 1/2 · Milton S. Hershey Medical Center

  UHC Sainte-Justine, Montreal

  Registry updated 2026-10-06

• NCT06760819

  A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  Trial Treatment · Phase 2 · Bayer

  Queen Elizabeth II Health Sciences Centre | Oncology, Halifax · Research Institute of the McGill University Health Centre | Women Health's Research Unit, Montreal · Princess Margaret Cancer Centre | Medical Oncology and Hematology, Toronto

  Registry updated 2026-10-02

• NCT07602777

  A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

  Trial Treatment · Phase 1/2 · GlaxoSmithKline

  GSK Investigational Site, Montreal · GSK Investigational Site, Toronto

  Registry updated 2026-10-01

• NCT06884618

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

  Trial Treatment · Phase 1 · Hoffmann-La Roche

  Princess Margaret Hospital, Toronto

  Registry updated 2026-09-28

• NCT04094610

  A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  Trial Treatment · Phase 1/2 · Turning Point Therapeutics, Inc.

  University Of Calgary, Calgary · Stollery Children'S Hospital, Edmonton · St Justine Hospital, Montreal · Children'S Hospital Of Eastern Ontario, Ottawa

  Registry updated 2026-09-25

• NCT04273061

  Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

  Trial Treatment · Phase 2 · British Columbia Cancer Agency

  University Health Network - Princess Margaret Cancer Centre, Toronto · BC Cancer, Vancouver

  Registry updated 2026-09-16

• NCT07156565

  Actinium Therapy for Late-stage Aggressive Sarcomas

  Trial Treatment · Phase 1 · Ratio Therapeutics, Inc.

  Princess Margaret Cancer Centre, Toronto

  Registry updated 2026-08-28

• NCT05235165

  Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  Trial Treatment · Phase 3 · Children's Oncology Group

  Alberta Children's Hospital, Calgary · University of Alberta Hospital, Edmonton · IWK Health Centre, Halifax · The Montreal Children's Hospital of the MUHC, Montreal · Centre Hospitalier Universitaire Sainte-Justine, Montreal · Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke

  Registry updated 2026-08-25

• NCT05304585

  Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  Trial Treatment · Phase 3 · Children's Oncology Group

  Alberta Children's Hospital, Calgary · University of Alberta Hospital, Edmonton · IWK Health Centre, Halifax · Centre Hospitalier Universitaire Sainte-Justine, Montreal · The Montreal Children's Hospital of the MUHC, Montreal · CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Québec · Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke · Hospital for Sick Children, Toronto · British Columbia Children's Hospital, Vancouver · CancerCare Manitoba, Winnipeg

  Registry updated 2026-08-25

• NCT07466316

  A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

  Trial Treatment · Phase 3 · Children's Oncology Group

  Centre Hospitalier Universitaire Sainte-Justine, Montreal

  Registry updated 2026-08-25

• NCT06263231

  A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

  Trial Treatment · Phase 3 · Intensity Therapeutics, Inc.

  Princess Margaret Cancer Centre, Toronto

  Registry updated 2026-08-11

• NCT07377747

  Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

  Research · Australia and New Zealand Sarcoma Association

  The Princess Margaret Cancer Centre, Toronto

  Registry updated 2026-07-15

• NCT03818412

  Circulating Tumor DNA in Soft Tissue Sarcoma

  Trial Treatment · University Health Network, Toronto

  Princess Margaret Cancer Centre, Toronto

  Registry updated 2026-06-23

• NCT07014137

  A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas

  Trial Treatment · Phase 2 · University Health Network, Toronto

  UHN- Princess Margaret Cancer Center, Toronto

  Registry updated 2026-06-04

• NCT07223047

  A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

  Trial Treatment · Phase 1/2 · Bristol-Myers Squibb

  Princess Margaret Cancer Centre, Toronto · BC Cancer - Vancouver, Vancouver

  Registry updated 2026-05-28

All Sarcoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error